JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Tessa Romero maintains a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and lowers the price target from $33 to $32.
August 07, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on Agios Pharmaceuticals and lowered the price target from $33 to $32.
The lowering of the price target by JP Morgan, a major financial institution, could potentially lead to a decrease in the stock price of Agios Pharmaceuticals in the short term. This is because the new price target suggests a lower valuation for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100